BACKGROUND: Schwannomatosis is a disease characterized by multiple non-vestibular schwannomas. Although biallelic NF2 mutations are found in schwannomas, no germ line event is detected in schwannomatosis patients. In contrast, germline mutations of the SMARCB1 (INI1) tumor suppressor gene were described in familial and sporadic schwannomatosis patients. METHODS: To delineate the SMARCB1 gene contribution, the nine coding exons were sequenced in a series of 56 patients affected with a variable number of non-vestibular schwannomas. RESULTS: Nine variants scattered along the sequence of SMARCB1 were identified. Five of them were classified as deleterious. All five patients carrying a SMARCB1 mutation had more multiple schwannomas, corresponding to 10.2% of patients with schwannomatosis. They were also diagnosed before 35 years of age. CONCLUSIONS: These results suggest that patients with schwannomas have a significant probability of carrying a SMARCB1 mutation. Combined with data available from other studies, they confirm the clinical indications for genetic screening of the SMARCB1 gene.
BACKGROUND:Schwannomatosis is a disease characterized by multiple non-vestibular schwannomas. Although biallelic NF2 mutations are found in schwannomas, no germ line event is detected in schwannomatosispatients. In contrast, germline mutations of the SMARCB1 (INI1) tumor suppressor gene were described in familial and sporadic schwannomatosispatients. METHODS: To delineate the SMARCB1 gene contribution, the nine coding exons were sequenced in a series of 56 patients affected with a variable number of non-vestibular schwannomas. RESULTS: Nine variants scattered along the sequence of SMARCB1 were identified. Five of them were classified as deleterious. All five patients carrying a SMARCB1 mutation had more multiple schwannomas, corresponding to 10.2% of patients with schwannomatosis. They were also diagnosed before 35 years of age. CONCLUSIONS: These results suggest that patients with schwannomas have a significant probability of carrying a SMARCB1 mutation. Combined with data available from other studies, they confirm the clinical indications for genetic screening of the SMARCB1 gene.
Authors: M MacCollin; E A Chiocca; D G Evans; J M Friedman; R Horvitz; D Jaramillo; M Lev; V F Mautner; M Niimura; S R Plotkin; C N Sang; A Stemmer-Rachamimov; E S Roach Journal: Neurology Date: 2005-06-14 Impact factor: 9.910
Authors: I Christiaans; S B Kenter; H C Brink; T A M van Os; F Baas; P van den Munckhof; A M J Kidd; T J M Hulsebos Journal: J Med Genet Date: 2010-10-07 Impact factor: 6.318
Authors: Theo J M Hulsebos; Astrid S Plomp; Ruud A Wolterman; Els C Robanus-Maandag; Frank Baas; Pieter Wesseling Journal: Am J Hum Genet Date: 2007-02-16 Impact factor: 11.025
Authors: K D Hadfield; W G Newman; N L Bowers; A Wallace; C Bolger; A Colley; E McCann; D Trump; T Prescott; D G R Evans Journal: J Med Genet Date: 2008-02-19 Impact factor: 6.318
Authors: Tjitske Kleefstra; Jamie M Kramer; Kornelia Neveling; Marjolein H Willemsen; Tom S Koemans; Lisenka E L M Vissers; Willemijn Wissink-Lindhout; Michaela Fenckova; Willem M R van den Akker; Nael Nadif Kasri; Willy M Nillesen; Trine Prescott; Robin D Clark; Koenraad Devriendt; Jeroen van Reeuwijk; Arjan P M de Brouwer; Christian Gilissen; Huiqing Zhou; Han G Brunner; Joris A Veltman; Annette Schenck; Hans van Bokhoven Journal: Am J Hum Genet Date: 2012-06-21 Impact factor: 11.025
Authors: Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini Journal: Am J Med Genet A Date: 2013-02-07 Impact factor: 2.802
Authors: Miriam J Smith; Andrew J Wallace; Naomi L Bowers; Cecilie F Rustad; C Geoff Woods; Guy D Leschziner; Rosalie E Ferner; D Gareth R Evans Journal: Neurogenetics Date: 2012-03-22 Impact factor: 2.660
Authors: Pepijn van den Munckhof; Imke Christiaans; Susan B Kenter; Frank Baas; Theo J M Hulsebos Journal: Neurogenetics Date: 2011-10-26 Impact factor: 2.660
Authors: Rosario Caltabiano; Gaetano Magro; Agata Polizzi; Andrea Domenico Praticò; Andrea Ortensi; Valerio D'Orazi; Andrea Panunzi; Pietro Milone; Luigi Maiolino; Francesco Nicita; Gabriele Lorenzo Capone; Roberta Sestini; Irene Paganini; Mariella Muglia; Sebastiano Cavallaro; Salvatore Lanzafame; Laura Papi; Martino Ruggieri Journal: Childs Nerv Syst Date: 2017-04-01 Impact factor: 1.475
Authors: Irene Paganini; Vivian Y Chang; Gabriele L Capone; Jeremie Vitte; Matteo Benelli; Lorenzo Barbetti; Roberta Sestini; Eva Trevisson; Theo Jm Hulsebos; Marco Giovannini; Stanley F Nelson; Laura Papi Journal: Eur J Hum Genet Date: 2014-10-22 Impact factor: 4.246
Authors: Arkadiusz Piotrowski; Jing Xie; Ying F Liu; Andrzej B Poplawski; Alicia R Gomes; Piotr Madanecki; Chuanhua Fu; Michael R Crowley; David K Crossman; Linlea Armstrong; Dusica Babovic-Vuksanovic; Amanda Bergner; Jaishri O Blakeley; Andrea L Blumenthal; Molly S Daniels; Howard Feit; Kathy Gardner; Stephanie Hurst; Christine Kobelka; Chung Lee; Rebecca Nagy; Katherine A Rauen; John M Slopis; Pim Suwannarat; Judith A Westman; Andrea Zanko; Bruce R Korf; Ludwine M Messiaen Journal: Nat Genet Date: 2013-12-22 Impact factor: 38.330